TL32711: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 24 evaluable patients with solid tumors or lymphoma showed that once-weekly 0.18-17.2 mg/m 2 doses of IV TL32711 for 3 consecutive weeks as part o...